Condition Event News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Condition Event. Real-time updates on events, politics, business and more.

EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

March 20, 2023

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation...

United States New Zealand United Kingdom Comunidad Autonoma De Cataluna Haruo Naito Ivan Cheung

Source: prnewswire.com

Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal

March 20, 2023

/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced the publication of updated results from an evaluation estimating...

United States Uppsala Lan Comunidad Autonoma De Cataluna Oskar Bosson Uppsala University Vp Communications

Source: prnewswire.com

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

June 22, 2022

Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation ModelingTOKYO, June 22, 2022 - (JCN Newswire) - Eisai Co., Ltd. today announced publication

United States Comunidad Autonoma De Cataluna Ivan Cheung Libby Holman Evidence Forum Eisai Inc

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Condition Event News Today

EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

Explore More Categories